Genzyme Corp. is dropping further work on its advanced phosphate binder (APB) - the product expected to save the Cambridge, Mass.-based firm's renal franchise from the looming patent cliff - after it failed to show improvement over Renvela in a Phase II/III trial, leaving analysts and investors to wonder what's next for the big biotech, which has suffered more than its share of bad news in the past several months. (BioWorld Today) Read More
